Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Veeva Systems: Worth Keeping an Eye on

Stock MarketsSep 17, 2021 01:00PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. Veeva Systems: Worth Keeping an Eye on

Veeva Systems (NYSE:VEEV) is a cloud-based software as a service (SaaS) company that targets the life sciences industry. The platform helps drugmakers develop drugs more efficiently, market the drugs to doctors, and maintain compliance with regulations.

Veeva has seen consistently strong top-line growth in the past decade. In 2021, revenue grew by 32.7%, with 72.1% gross margins and 25.8% profit margins.

However, the stock trades at a premium of 114.6 times earnings. As we continue to approach October, a historically volatile period for the stock market, we place a neutral rating on Veeva Systems because its high multiple may make it vulnerable to unwanted drawdowns. (See Veeva stock charts on TipRanks).

What We Like

There are a couple of things that are very interesting about Veeva. The first is that its vertically integrated, specifically for the life sciences industry. Since this is a complex and highly regulated industry, horizontally integrated (general use across multiple industries) platforms are often not good enough to be used on their own.

As a result, drug makers would likely have to mix and match different platforms, or create their own, which can be expensive. However, by specializing in this complex industry, Veeva has essentially become the go-to provider for major companies such as Eli Lilly (NYSE:LLY) and Merck (MRK).

The second interesting point is how the company integrates sales and research. Companies use the platform to manage internal documents and processes related to drug development to make collaborating easier among different departments.

The internal documents that show the efficacy and other relevant trial results can be made available for salespeople to easily access when trying to sell to doctors and hospitals. This makes the sales team's job much easier.

Growth Catalysts

Veeva operates in the healthcare IT industry which is expected to grow at a CAGR of 10.7% from 2021 to 2028. We consider this to be high growth for an entire industry that is currently worth $74.2 billion. Thus, the increasing reliance on data and software is a clear tailwind for the company.

Furthermore, since Veeva's platform is specialized for a complex industry, it makes the cost of switching expensive. Even if a similar competitor emerges, customers of Veeva may not think it's worth switching over, simply because of the amount of data that is already stored in Veeva's platform.

In addition, employees would need to be retrained on the new platform, which takes away from productivity.


A potential long-term risk that we see in Veeva is that by continuing to specialize in a very specific niche within the healthcare IT industry, it may be limiting its potential for growth.

However, the company generates healthy profits and would likely have the resources to expand into complementary industries if growth were to slow down significantly.

In addition, the risk of competition is always there. Even if Veeva currently has a strong position in the market, it still needs to invest in innovation in order to stay ahead of the competition.

As we previously mentioned, customers may not want to switch over to competitors that are similar to the company. However, they will likely switch over to competitors that become significantly better.

Wall Street’s Take

Turning to Wall Street, Veeva has a Moderate Buy consensus rating, based on eight Buys, two Holds and zero Sells assigned in the last three months. The average Veeva price target of $350.13 implies 14.7% upside potential.

Final Thoughts

Veeva is a great company. However, its current multiple (even if investors believe it's justified) does make it vulnerable to drawdowns in periods of volatility, which historically have happened around this time of the year.

Disclosure: At the time of publication, Stock Bros Research did not have a position in any of the securities mentioned in this article.

​Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

Veeva Systems: Worth Keeping an Eye on

Related Articles

Buy early for Christmas, Puma tells shoppers
Buy early for Christmas, Puma tells shoppers By Reuters - Oct 27, 2021

By Emma Thomasson BERLIN (Reuters) - German sportswear company Puma on Wednesday advised people to shop early for Christmas as supply bottlenecks and manufacturing disruptions...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email